Animal spirits are starting to return to Novavax (NVAX) based on the posts on StockTwits. The bullish sentiment is now close to 100%. The small biotech doesn't have many catalysts over the next 6 months. The quarterly results at the end of February will provide insight on the cash burn rate. The top line results for the new Phase 2 Resolve clinical trial isn't expected until Q3 and the Phase 3 results for the RSV for infants isn't expected until towards the end of the year. Biotech stocks usually run prior to expected positive outcomes on clinical trials, but the investor base in Novavax appears too bullish here knowing that cash questions remain and positive Phase 2 results in the past were a false signal. Disclosure: No position